Large reduction in attack frequency
From weeks 1 to 25, the reported mean attack rate was 81% lower with four-week dosing and 55% lower with eight-week dosing than with placebo, with confidence intervals and P values supplied.
↳ Abstract, Results
Abstract
BACKGROUND: Hereditary angioedema is a rare disorder characterized by episodic, potentially life-threatening swelling caused by kallikrein-kinin dysregulation. Long-term prophylaxis can stabilize this system. Donidalorsen, an antisense oligonucleotide, specifically reduces prekallikrein expression.
METHODS: In this phase 3, double-blind, randomized trial, we assigned patients with hereditary angioedema to receive donidalorsen (80 mg subcutaneously) or placebo once every 4 or 8 weeks. The primary end point was the time-normalized number of investigator-confirmed hereditary angioedema attacks per 4 weeks (attack rate) from week 1 to week 25.
RESULTS: A total of 90 patients received donidalorsen every 4 weeks (45 patients), donidalorsen every 8 weeks (23 patients), or placebo (22 patients). The least-squares mean time-normalized attack rate was 0.44 (95% CI, 0.27 to 0.73) in the 4-week group, 1.02 (95% CI, 0.65 to 1.59) in the 8-week group, and 2.26 (95% CI, 1.66 to 3.09) in the placebo group. The mean attack rate from week 1 to week 25 was 81% lower (95% CI, 65 to 89) in the 4-week group than in the placebo group (P<0.001) and 55% lower (95% CI, 22 to 74) in the 8-week group than in the placebo group (P = 0.004); the median reduction in the attack rate from baseline was 90% in the 4-week group, 83% in the 8-week group, and 16% in the placebo group. The mean attack rate during weeks 5 to 25 was 87% lower (95% CI, 72 to 94) in the 4-week group than in the placebo group (P<0.001) and 60% lower (95% CI, 25 to 79) in the 8-week group than in the placebo group. Donidalorsen administered every 4 weeks resulted in an improvement in the least-squares mean total score for the change at week 25 on the Angioedema Quality-of-Life Questionnaire (scores range from 0 to 100, with a score of 100 indicating the worst possible quality of life) that was 18.6 points (95% CI, 9.5 to 27.7) better than that with placebo (P<0.001). The most common adverse events were erythema at the injection site, headache, and nasopharyngitis; 98% of adverse events were mild or moderate in severity.
CONCLUSIONS: Donidalorsen treatment reduced the hereditary angioedema attack rate, a finding that supports potential prophylactic use for hereditary angioedema. (Funded by Ionis Pharmaceuticals; OASIS-HAE ClinicalTrials.gov number, NCT05139810.).
Key Claims
Primary findingSupported
The mean attack rate from week 1 to week 25 was 81% lower (95% CI, 65 to 89) in the 4-week group than in the placebo group (P<0.001)
Possible — the claim's weakest requirement is that it holds beyond the sample studied. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
randomized comparison directly supports the effect, but full analysis and attrition procedures are unavailable
Abstract, Results
SecondarySupported
The mean attack rate from week 1 to week 25 was 55% lower (95% CI, 22 to 74) in the 8-week group than in the placebo group (P = 0.004)
randomized comparison supports the direction, with a small treatment arm and unavailable full analysis details
Abstract, Results
SecondarySupported
Donidalorsen administered every 4 weeks resulted in an improvement in the least-squares mean total score that was 18.6 points (95% CI, 9.5 to 27.7) better than that with placebo (P<0.001)
the secondary endpoint favors treatment, but multiplicity and measurement procedures cannot be checked
Abstract, Results
SecondarySupported
The most common adverse events were erythema at the injection site, headache, and nasopharyngitis; 98% of adverse events were mild or moderate in severity
the abstract reports systematic adverse-event findings, but complete event and serious-harm tables are unavailable
Abstract, Results
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Controlled late-stage clinical design
The Abstract identifies a Phase 3, randomized, double-blind comparison against placebo and defines the primary endpoint as investigator-confirmed attacks normalized over time.
↳ Abstract, Methods
Quantified and restrained reporting
Efficacy, quality-of-life, and adverse-event findings are reported numerically, while the conclusion limits itself to supporting potential prophylactic use.
↳ Abstract, Results and Conclusions
Limitations
Core execution details remain unavailable
The supplied full-text record contains metadata rather than the manuscript body, preventing assessment of allocation concealment, analysis populations, attrition, multiplicity, and complete harms procedures.
↳ Supplied Full Text repository record
Treatment landscape is not assessable
The Abstract gives biological background but does not compare donidalorsen with established hereditary angioedema prophylaxis or delineate the advance against the closest prior trials.
↳ Abstract, Background; supplied Full Text repository record
Broader generalizability remains uncertain
Only 90 patients are reported, including 22 in the placebo group and 23 in the eight-week group, while site diversity and subgroup consistency are not visible.
↳ Abstract, Results
Nabu Commentary
The defined primary endpoint and randomized, double-blind, placebo-controlled design support a competent late-stage efficacy assessment. Reported attack-rate reductions are large and internally consistent with the least-squares mean rates, while the conclusion remains appropriately limited to potential prophylactic use. The score is constrained mainly by the repository record’s omission of the manuscript body, which prevents verification of allocation, attrition, multiplicity, detailed harms, and limitation handling. The 90-patient sample also leaves transferability less established than the primary efficacy signal.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Sound3.6
Confidence mediumContribution
3.8
The study reports Phase 3 randomized evidence for an antisense prophylactic with substantial attack-rate reductions under two dosing schedules. The advance is clinically meaningful, although the supplied record does not show how the paper distinguishes itself from existing prophylactic options.
Abstract, Background and Results
“Donidalorsen, an antisense oligonucleotide, specifically reduces prekallikrein expression.”
Methodological Rigour
3.6
The visible design is randomized, double-blind, placebo-controlled, and organized around a defined investigator-confirmed primary endpoint. The absent manuscript body prevents assessment of allocation concealment, attrition handling, multiplicity procedures, and complete adverse-event reporting.
Abstract, Methods; supplied Full Text repository record
“The primary end point was the time-normalized number of investigator-confirmed hereditary angioedema attacks per 4 weeks.”
Reporting
4.0
The Abstract connects the endpoint to arm-specific estimates, confidence intervals, P values, quality-of-life results, and a measured conclusion. Its wording remains below the highest band because coherence and calibration across the full paper cannot be inspected.
Abstract, Results and Conclusions
“a finding that supports potential prophylactic use for hereditary angioedema”
Positioning
3.0
The Abstract explains hereditary angioedema and the intervention’s biological mechanism, providing basic clinical and mechanistic context. It does not visibly compare competing prophylactic options or present a limitations discussion because the manuscript body is absent.
Abstract, Background; supplied Full Text repository record
“Hereditary angioedema is a rare disorder characterized by episodic, potentially life-threatening swelling”
Lower confidence on Methodological Rigour, Positioning — domain match limited.
Reliability
No concerns3 of 4 checks
Internal CoherenceClean
The efficacy estimates, percentage reductions, confidence intervals, and conclusions reported in the Abstract are mutually coherent. No contradiction or impossible statistic was identified in the supplied text.
Research ConductClean
The Abstract identifies industry funding and the ClinicalTrials.gov registration number. Ethics, full conflict-of-interest, data-availability, and code-availability information cannot be evaluated because the supplied full-text record contains only metadata and the abstract.
Flags: 1 declared / 5 total
Reference IntegrityNot checked
Reference integrity check could not run: no references section detected in extracted text.
0 references in manuscript
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 18 Sep 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Deployable
A completed Phase 3 randomized trial in patients places the intervention close to practice-relevant translation. Implementation guidance, comparative effectiveness, and longer-term follow-up are not visible in the supplied record.
Abstract, Methods and Results
“In this phase 3, double-blind, randomized trial”
AI-generated, human-governed. Something look off? Contact us to request a review.